We analyzed the available evidence on semaglutide and cardiovascular events in people who are overweight or obese but do not have diabetes. What we’ve found so far is that 45.0 studies or assertions support the idea that semaglutide lowers the risk of serious heart-related events like heart attack or stroke in this group, with no studies contradicting this finding [1]. The evidence suggests this benefit may happen even when some of the effect isn’t directly tied to weight loss, meaning semaglutide might influence heart health through other pathways, such as reducing inflammation, improving blood pressure, or affecting how the body uses fat and sugar. We don’t know exactly how these changes occur, but the pattern across the data points to a consistent association between taking semaglutide and fewer major cardiovascular events. It’s important to note that all the evidence we’ve reviewed comes from a single category of support — there are no studies in our analysis that show no benefit or harm. That doesn’t mean the effect is guaranteed for everyone, but it does mean the current data doesn’t show any counterexamples. We can’t say whether this benefit will last over many years, or how it compares to other approaches like diet, exercise, or different medications. The studies we’ve seen focus on specific populations and timeframes, and we don’t have long-term data beyond what’s been reported. For someone who is overweight or obese and concerned about heart health, this suggests semaglutide could be one option worth discussing with a healthcare provider — especially if other strategies haven’t been enough. But it’s not a substitute for healthy habits, and the decision should consider individual health goals, risks, and preferences.